Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Trial Identifier: D967YC00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo, Inc.
Start Date: March 2021
Primary Completion Date: December 2025
Study Completion Date: December 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations